Linklaters advises Zylox-Tonbridge on acquisition of equity interest in LifeTech Scientific Corporation and new share issuance

Linklaters has advised Zylox-Tonbridge Medical Technology Co., Ltd. (Zylox-Tonbridge) on its acquisition of an equity interest in LifeTech Scientific Corporation (LifeTech) via a joint venture with GL Capital and related issuance of new H shares to GL Capital.

Upon completion of the transactions, Zylox-Tonbridge will indirectly hold approximately 16.7% of the voting rights in LifeTech and an effective interest of approximately 10%.

Zylox-Tonbridge and LifeTech are leading China-based innovative medical device companies, specialised in vascular and cardiac intervention, both listed on the Hong Kong Stock Exchange. GL Capital is an investment fund specialised in China healthcare.

The multidisciplinary Linklaters team was led by capital markets partner Oliver Zhong and corporate partners Betty Yap, Roger Cheng and Queenie Tong, supported by Jiang Zhao, Mori Cheng, Peony Leung and Yujie Wen. Specialist advice was provided by Xi Liao and Larry Zhou of Zhao Sheng Law Firm, Linklaters’ joint operation firm in China, on antitrust matters, and by Joshua Li on employment law matters.

With more than 50 years of on-the-ground experience in Hong Kong SAR and across Asia, Linklaters combines deep local insight with the strength of its global platform. Its cross-practice and multijurisdictional teams bring together Corporate/M&A, capital markets and specialist expertise to support clients on complex, integrated transactions across the region